Literature DB >> 10970391

Comparison of Escherichia coli O157:H7 antigen detection in stool and broth cultures to that in sorbitol-MacConkey agar stool cultures.

J R Stapp1, S Jelacic, Y L Yea, E J Klein, M Fischer, C R Clausen, X Qin, D L Swerdlow, P I Tarr.   

Abstract

We evaluated the Meridian IC-STAT direct fecal and broth culture antigen detection methods with samples from children infected with Escherichia coli O157:H7 and correlated the antigen detection results with the culture results. Stools of 16 children who had recently had stool cultures positive for this pathogen (population A) and 102 children with diarrhea of unknown cause (population B) were tested with the IC-STAT device (direct testing). Fecal broth cultures were also tested with this device (broth testing). The results were correlated to a standard of the combined yield from direct culture of stools on sorbitol-MacConkey (SMAC) agar and culture of broth on SMAC agar. Eleven (69%) of the population A stool specimens yielded E. coli O157:H7 when plated directly on SMAC agar. Two more specimens yielded this pathogen when the broth culture was similarly plated. Of these 13 stool specimens, 8 and 13 were positive by direct and broth testing (respective sensitivities, 62 and 100%). Compared to the sensitivity of a simultaneously performed SMAC agar culture, the sensitivity of direct testing was 73%. Three (3%) of the population B stool specimens contained E. coli O157:H7 on SMAC agar culture; one and three of these stool specimens were positive by direct and broth testing, respectively. The direct and broth IC-STAT tests were 100% specific with samples from children from population B. Direct IC-STAT testing of stools is rapid, easily performed, and specific but is insufficiently sensitive to exclude the possibility of infection with E. coli O157:H7. Performing the IC-STAT test with a broth culture increases its sensitivity. However, attempts to recover E. coli O157:H7 by culture should not be abandoned but, rather, should be increased when the IC-STAT test result is positive.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10970391      PMCID: PMC87394     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections.

Authors:  B P Bell; P M Griffin; P Lozano; D L Christie; J M Kobayashi; P I Tarr
Journal:  Pediatrics       Date:  1997-07       Impact factor: 7.124

2.  Isolation of enterohemorrhagic Escherichia coli O157 strains from patients with hemolytic-uremic syndrome by using immunomagnetic separation, DNA-based methods, and direct culture.

Authors:  H Karch; C Janetzki-Mittmann; S Aleksic; M Datz
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

3.  Escherichia coli O157:H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology.

Authors:  P I Tarr; M A Neill; C R Clausen; S L Watkins; D L Christie; R O Hickman
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

4.  The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.

Authors:  C S Wong; S Jelacic; R L Habeeb; S L Watkins; P I Tarr
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

5.  Performance of the ImmunoCard STAT! E. coli O157:H7 test for detection of Escherichia coli O157:H7 in stools.

Authors:  A Mackenzie; E Orrbine; L Hyde; M Benoit; F Chan; C Park; J Alverson; A Lembke; D Hoban; W Kennedy
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

6.  Isolation of Shiga-like toxin producing Escherichia coli (O157 and non-O157) in a community hospital.

Authors:  C H Park; K M Gates; N M Vandel; D L Hixon
Journal:  Diagn Microbiol Infect Dis       Date:  1996-10       Impact factor: 2.803

7.  Surveillance for Escherichia coli O157:H7 infections in Minnesota by molecular subtyping.

Authors:  J B Bender; C W Hedberg; J M Besser; D J Boxrud; K L MacDonald; M T Osterholm
Journal:  N Engl J Med       Date:  1997-08-07       Impact factor: 91.245

8.  A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome.

Authors:  G D Armstrong; P C Rowe; P Goodyer; E Orrbine; T P Klassen; G Wells; A MacKenzie; H Lior; C Blanchard; F Auclair
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

9.  Sorbitol-MacConkey medium for detection of Escherichia coli O157:H7 associated with hemorrhagic colitis.

Authors:  S B March; S Ratnam
Journal:  J Clin Microbiol       Date:  1986-05       Impact factor: 5.948

Review 10.  Escherichia coli O157:H7: clinical, diagnostic, and epidemiological aspects of human infection.

Authors:  P I Tarr
Journal:  Clin Infect Dis       Date:  1995-01       Impact factor: 9.079

  10 in total
  5 in total

1.  Importance of testing stool specimens for Shiga toxins.

Authors:  C H Park; H J Kim; D L Hixon
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

2.  Role of the laboratory in the diagnosis of enterohemorrhagic Escherichia coli infections.

Authors:  Sue C Kehl
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

3.  Evaluation of BBL CHROMagar O157 versus sorbitol-MacConkey medium for routine detection of Escherichia coli O157 in a centralized regional clinical microbiology laboratory.

Authors:  D L Church; D Emshey; H Semeniuk; T Lloyd; J D Pitout
Journal:  J Clin Microbiol       Date:  2007-07-18       Impact factor: 5.948

Review 4.  Diagnosis and treatment of bacterial diarrhea.

Authors:  James V Lawler; Mark R Wallace
Journal:  Curr Gastroenterol Rep       Date:  2003-08

5.  Clinical and Laboratory Predictors of Shiga Toxin-Producing Escherichia coli Infection in Children With Bloody Diarrhea.

Authors:  Ryan S McKee; Phillip I Tarr; Dennis J Dietzen; Rachit Chawla; David Schnadower
Journal:  J Pediatric Infect Dis Soc       Date:  2018-08-17       Impact factor: 3.164

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.